ReviewInternational journal of urology : official journal of the Japanese Urological Association2019
Particle therapy for prostate cancer: The past, present and future.
Review in International journal of urology : official journal of the Japanese Urological Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.International journal of urology : official journal of the Japanese Urological Association · 2024Pooled it
- A Japanese registry study and systematic review of particle therapy for renal cell carcinoma.Journal of radiation research · 2023Pooled it
- Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.Cancer science · 2021Trial
- Safety of carbon-ion radiotherapy for prostate cancer after rectal surgery: a single-institution retrospective study.Journal of radiation research · 2026Article
- Feasibility and safety of Taipei Veterans General Hospital Heavy Ion Therapy Center: The first carbon-ion irradiation facility in Taiwan.Journal of the Chinese Medical Association : JCMA · 2025Article
- A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer.Advances in radiation oncology · 2025Article
- Optimizing the dose-averaged linear energy transfer for the dominant intraprostatic lesions in high-risk localized prostate cancer patients.Physics and imaging in radiation oncology · 2025Article
- Overall Survival and Cancer-Specific Mortality in Patients with Prostate Cancer Undergoing Definitive Therapies: A Narrative Review.Journal of clinical medicine · 2024Review
- Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy.Current oncology (Toronto, Ont.) · 2023Article
- Article
- Carbon-ion radiotherapy for urological cancers.International journal of urology : official journal of the Japanese Urological Association · 2022Review
- Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer.Cancers · 2022Article
- Estimation of biological effect of Cu-64 radiopharmaceuticals with Geant4-DNA simulation.Scientific reports · 2022Article
- Article
- Towards real-time PGS range monitoring in proton therapy of prostate cancer.Scientific reports · 2021Article
- Who Will Benefit from Charged-Particle Therapy?Cancer research and treatment · 2021Review
- Changes in sexual function and serum testosterone levels in patients with prostate cancer after image-guided proton therapy.Journal of radiation research · 2021Article
- Conversion and validation of rectal constraints for prostate carcinoma receiving hypofractionated carbon-ion radiotherapy with a local effect model.Radiation oncology (London, England) · 2021Article
- Preliminary analysis of prostate positional displacement using hydrogel spacer during the course of proton therapy for prostate cancer.Journal of radiation research · 2021Article
- Quantitative estimation of track segment yields of water radiolysis species under heavy ions around Bragg peak energies using Geant4-DNA.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Although prostate cancer control using radiotherapy is dose-dependent, dose-volume effects on late toxicities in organs at risk, such as the rectum and bladder, have been observed. Both protons and carbon ions offer advantageous physical properties for radiotherapy, and create favorable dose distributions using fewer portals compared with photon-based radiotherapy. Thus, particle beam therapy using protons and carbon ions theoretically seems suitable for dose escalation and reduced risk of toxicity. However, it is difficult to evaluate the superiority of particle beam radiotherapy over photon beam radiotherapy for prostate cancer, as no clinical trials have directly compared the outcomes between the two types of therapy due to the limited number of facilities using particle beam therapy. The Japanese Society for Radiation Oncology organized a joint effort among research groups to establish standardized treatment policies and indications for particle beam therapy according to disease, and multicenter prospective studies have been planned for several common cancers. Clinical trials of proton beam therapy for intermediate-risk prostate cancer and carbon-ion therapy for high-risk prostate cancer have already begun. As particle beam therapy for prostate cancer is covered by the Japanese national health insurance system as of April 2018, and the number of facilities practicing particle beam therapy has increased recently, the number of prostate cancer patients treated with particle beam therapy in Japan is expected to increase drastically. Here, we review the results from studies of particle beam therapy for prostate cancer and discuss future developments in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.